Acute Respiratory Distress Syndrome (ARDS) Market Anticipating Remarkable Growth by 2032, Insights by DelveInsight | BioAegis Therapeutics (Gelsolin/ rhu-pGSN), Abbreos, Athersys, Aviceda, Bayer, Boehringer Ingelheim,Cynata, Genentech, Healios, ILTOO

The Acute Respiratory Distress Syndrome (ARDS) market is undergoing notable evolution driven by advancements in critical care management, innovative therapeutic strategies, and improved understanding of the underlying pathophysiology, promising enhanced outcomes for affected patients. Ongoing research endeavors and growing emphasis on early detection and intervention are reshaping the landscape, ushering in new possibilities for the treatment and management of this complex condition.

DelveInsight's "Acute Respiratory Distress Syndrome (ARDS) Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Acute Respiratory Distress Syndrome Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Acute Respiratory Distress Syndrome therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Acute Respiratory Distress Syndrome treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Acute Respiratory Distress Syndrome (ARDS): An Overview
Acute respiratory distress syndrome (ARDS) is a rapidly progressive disease occurring in critically ill patients. The major complication in ARDS is marked by leakage of fluid into the lungs, making breathing difficult or impossible. Acute lung injury (ALI) is a common condition characterized by acute severe hypoxia that is not due to left atrial hypertension. The term ALI encompasses a continuum of clinical and radiographic changes that affect the lungs with the ARDS representing the more severe end of this continuum. Despite advances in the understanding of the pathophysiology and management of ALI, it is still associated with high mortality.

The market is expected to grow, driven by the factors like increase in the incident pool, expected entry of emerging therapies such as EB05, BIO-11006, MultiStem, Alteplase, Lucinactant, and EXOFLO (DB-001), among others in the 7MM markets. The increase in market size is also a consequence of a rise in awareness and disease understanding. Apart from above mentioned molecules, BDB-001, Zavegepant, Metablok, Veru-111, PLX-PAD, among others are the other pipeline therapies, which are expected to enter the market in the coming years targeting the COVID-19 associated ARDS.

Acute Respiratory Distress Syndrome (ARDS) Market Key Facts
• The United States accounts for the largest market size for Acute Respiratory Distress Syndrome compared to EU5 (Germany, Italy, France, Spain, and the United Kingdom) and Japan.
• Among the EU5 countries, Germany had the highest market size, with approximately USD 166.2 million, followed by France in 2021.
• In 2021, the total incident cases of ARDS were estimated to be 1,088,000+ cases in the 7MM. These cases are expected to increase by 2032 at a CAGR of 1.5% during the study period (2019-2032).
• Among the 7MM, the United States has the highest number of incident cases of ARDS, with approximately 630,000+ cases in 2021.
• Generally, among the 7MM countries, the primary risk factor associated with the highest number of incident cases of ARDS was pneumonia, except for the United Kingdom, where sepsis was the primary risk factor for ARDS
• Among the EU-5, Germany had the highest total incident population of ARDS with 193,828 cases, followed by France (73,541 cases) and Italy with 55,522 cases in 2021. On the other hand, Spain (31,286 cases) had the lowest incident population for 2021.
• In 2021, Japan had approximately 69,628 total incident cases of ARDS, which are expected to increase by 2032 at a CAGR of 0.5% during the study period (2019-2032).

Get a Detailed Overview of the Evolving Acute Respiratory Distress Syndrome Market Trends @
https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Acute Respiratory Distress Syndrome (ARDS) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Acute Respiratory Distress Syndrome therapies in the market. It also provides a detailed assessment of the Acute Respiratory Distress Syndrome market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete details of the market trend for each marketed Acute Respiratory Distress Syndrome drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How the Acute Respiratory Distress Syndrome Market Will Grow by 2032 @
https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Acute Respiratory Distress Syndrome (ARDS) Epidemiology
The epidemiology section covers detailed insights into the historical, and current Acute Respiratory Distress Syndrome patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Acute Respiratory Distress Syndrome Epidemiology Segmented as -
• Total Incident Population of Acute Respiratory Distress Syndrome
• Incident Population of Acute Respiratory Distress Syndrome (ARDS) by risk factors
• Severity-specific Incident Population of Acute Respiratory Distress Syndrome

Get Key Insights Into the Evolving Acute Respiratory Distress Syndrome Epidemiology Trends @
https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Acute Respiratory Distress Syndrome (ARDS) Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acute Respiratory Distress Syndrome market or expected to be launched during the study period. The analysis covers the market share by Acute Respiratory Distress Syndrome drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Acute Respiratory Distress Syndrome Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities in the Acute Respiratory Distress Syndrome Market @
https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Acute Respiratory Distress Syndrome (ARDS) Therapeutics Assessment
Several major pharma and biotech companies are developing therapies for Acute Respiratory Distress Syndrome. Currently, Athersys is leading the therapeutics market with its Acute Respiratory Distress Syndrome drug candidates in the most advanced stage of clinical development.

On February 27, 2024, BioAegis Therapeutics announced site recruitment for BTI-203, a Phase 2 study of recombinant human gelsolin (rhu-pGSN) for the treatment of Acute Respiratory Distress Syndrome (ARDS) (NCT05947955).

Leading Companies in the Acute Respiratory Distress Syndrome Therapeutics Market Include
Abbreos, Aerpio Pharmaceuticals, Apeiron Biologics, APEPTICO Forschung und Entwicklung GmbH, Arch Biopartners, Athersys, Avalo Therapeutics, Aviceda Therapeutics, AVM Biotechnology, Bayer, Biohaven Pharmaceutical, BioMarck Pharmaceuticals, Boehringer Ingelheim, Cartesian Therapeutics, CohBar, Cynata Therapeutics, Direct Biologics, Edesa Biotech, Exvastat, Faron Pharmaceuticals, GEn1E Lifesciences, Genentech, Healios, ILTOO Pharma, ImStem Biotechnology, Light Chain Biosciences, Longeveron, MediciNova, Mesoblast Limited, Orbsen Therapeutics, Pluristem Therapeutics, Roivant Sciences, Sage Therapeutics, Staidson (Beijing) Biopharmaceuticals, Veru, Windtree Therapeutics, ZyVersa Therapeutics, and others.

Emerging and Marketed Acute Respiratory Distress Syndrome Therapies Covered in the Report Include
• Alteplase (Actilyse): Boehringer Ingelheim/ Genentech
• BIO-11006: BioMarck Pharmaceuticals
• EB05: Edesa Biotech
• ExoFlo (DB-001): Direct Biologics
• HCR040: Histocell, S.L.
• HLCM051(MultiStem): Healios
• MultiStem: Athersys
And Many More

Learn More About the Emerging Therapies and key Companies in the Acute Respiratory Distress Syndrome Therapeutics Market @

https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Acute Respiratory Distress Syndrome Competitive Intelligence Analysis
4. Acute Respiratory Distress Syndrome Market Overview at a Glance
5. Acute Respiratory Distress Syndrome Background and Overview
6. Acute Respiratory Distress Syndrome Patient Journey
7. Acute Respiratory Distress Syndrome Epidemiology and Patient Population
8. Acute Respiratory Distress Syndrome Treatment Algorithm, Current Treatment, and Medical Practices
9. Acute Respiratory Distress Syndrome Unmet Needs
10. Key Endpoints of Acute Respiratory Distress Syndrome Treatment
11. Acute Respiratory Distress Syndrome Marketed Products
12. Acute Respiratory Distress Syndrome Emerging Therapies
13. Acute Respiratory Distress Syndrome Seven Major Market Analysis
14. Attribute Analysis
15. Acute Respiratory Distress Syndrome Market Outlook (7 major markets)
16. Acute Respiratory Distress Syndrome Access and Reimbursement Overview
17. KOL Views on the Acute Respiratory Distress Syndrome Market.
18. Acute Respiratory Distress Syndrome Market Drivers
19. Acute Respiratory Distress Syndrome Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.